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Management of chronic liver disease and hepatocellular carci-
noma (HCC) in older age groups beyond the age of 70 years has
been changing in the past decade. The availability of a growing
spectrum of anti-viral agents for treatment of chronic viral hepa-
titis B and C as well the introduction of several non-surgical
modalities for loco-regional treatment of advanced HCC have
had a major impact on the clinical practice and survival of young
and old patients alike [1–3]. Cirrhosis of the liver is the most
common risk factor for HCC, irrespective of age. The pathophysi-
ology of cirrhosis and consequently also of HCC is driven by sev-
eral factors including the individual hepatic morbidities
associated with HCC (i.e., persistent viral infection, metabolic
and/or alcoholic liver disease), which have a variable clinical pre-
sentation at older age. The introduction of universal vaccination
against hepatitis B virus (HBV) infection in over 170 countries
is already leading to a decrease in the incidence of hepatitis B
and HCC worldwide. Yet, the incidence of HCC is expected to rise
in the next decades due to the current inability to control the pro-
gression of hepatitis C virus (HCV) infection on a global scale. In
this context, it is important to note that the mean age of diagnosis
of HCC, especially in the Western hemisphere varies between 63
and 65 years as compared to 55–59 years in China [4]. The pro-
portion of HCC patients, 70 years and older, seeking treatment
has been rising steadily, especially in the US and Europe [4–6],
although there seems to be a shift of the peak of HCC incidence
in some regions to relatively younger age groups [7]. In the past
two decades, major progress has been made in the treatment of
HCC including the development of various effective ablation pro-
cedures for loco-regional injection, surgical resection and liver
transplantation as well as new chemotherapeutic agents [1,2].
Yet, clinicians often prefer a conservative approach when consid-
ering treatment options for elderly patients with HCC, even in the
presence of preserved synthetic liver functions and absence of
portal hypertension. The reluctance to offer invasive treatmentJournal of Hepatology 20
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Open access under CC BY-NC-ND license.modalities to the elderly patient is based in part on the notion
that molecular pathophysiologic changes of the aging liver pre-
dispose to a worse response to treatment, more adverse effects,
and less favorable prognosis as compared to younger individuals.
There is, however, limited evidence to support such a conserva-
tive approach. Indeed, data reported in aging animals and in older
humans suggest an increase in hepatocyte size, a rising number
of binucleated hepatocytes, a reduction in numbers of mitochon-
dria and oxidative capacity, a loss in hepatic volume and degree
of hepatic perfusion as well as a decline in regenerative capacity.
However, a recent paper by Sheedfar and co-workers entitled
‘‘Liver diseases and aging: friends or foes?’’ is casting doubt on
the practical therapeutic implications of these phenomena and
asking: ‘‘Is aging an actual risk factor for liver disease or a bystan-
der?’’ [8]. Indeed, current clinical experience suggests that vari-
ous ablation procedures for HCC including transarterial
chemoembolization (TACE), radiofrequency ablation (RFA) and
even surgical resection in the elderly patients are not less effec-
tive and safe as compared to younger cohorts of <65 years of
age [9–15].
In this context, it is also important to assess the safety and
effectiveness of transarterial radioembolization, referred to also
as selective internal radiation therapy (SIRS), using 90Ytrium in
the elderly population. Early versions of SIRS treatment were
already developed in the 1990s [16]. It took however more than
a decade to develop clinically usable compounds containing
either 90Y labeled glass or resin microspheres for intra-arterial
injection to the liver. SIRS has been evaluated in a number of clin-
ical trials in patients with unresectable HCC, in patients with
hepatic metastases of colorectal cancer, neuroendocrine tumors,
cholangiocarcinoma and metastatic carcinoma [17–24]. In a
recent retrospective comparative clinical trial, toxicity and sur-
vival were evaluated in 245 HCC patients treated by TACE and
123 patients treated by SIRS over a period of 9 years. A statisti-
cally non-signiﬁcant trend for a higher response rate was
observed in 49% of SIRS recipients as compared to 36% of TACE
treated patients (p = 0.104). Time to tumor progression was
longer following SIRS, 13.4 vs. 8.4 months (p = 0.046). Yet, median
survival was not statistically different, ranging between 20.5 and
17.4 months following SIRS and TACE respectively [19]. Abdomi-
nal pain and ‘‘transaminitis’’ were more frequent in TACE recipi-
ents (p <0.05). Until recently, limited data were reported13 vol. 59 j 643–645
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regarding safety and effectiveness of SIRS in the elderly HCC
patient [25].
In the present issue of the Journal, Dr Golﬁeri and co-workers
report the results of a European multicenter, retrospective study,
involving 8 centers, comparing the survival and safety of radio-
embolization between two cohorts of unresectable HCC patients
younger and older than 70 years [26]. The main results of this
study, performed on 128 elderly patients >70 years old and 197
younger patients <70 years of age, suggest a similar survival by
Kaplan-Meier analysis in both groups of 14.5 vs. 12.8 month
respectively in early, intermediate or advanced BCLC stage disease,
withanoverall comparable safety forbothprocedures.Mediansur-
vival in BCLC stage A patients was similar, 23.7 vs. 27.4 months in
older and younger SIRS recipients, dropping to 16.9 and
18.4 months in BCLC stage B patients and to 10.3 vs. 9.7 months
in BCLC stage C patients respectively. Thus, the main conclusion
of this study suggests that SIRS treatment is equally effective and
safe in elderly patients, 70 years and older as compared to younger
patients <70 years of age. This is most probably indeed the case.
However, The robustness of this conclusion is limited due to the
retrospective design of this study as also acknowledged by the
authors. Interestingly, elderlypatientshad smaller livers, hadmore
selective segmental interventions, and showed delayed tumor
growth, as compared to the younger population. This observation
is consistent with previous reports in aging experimental animals
and in humans, suggesting diminished hepatic perfusion and loss
of hepatic volume with advancing age [8].
Comments: Radioembolization for treatment of advanced HCC
has captured the attention of hepatologists, oncologists, and inva-
sive radiologists for more than a decade. SIRS is now available on a
commercial basis inmany countries. Consequently, relatively large
numbers of patients were and are being treated by SIRS although
data from large scale prospective randomized trials comparing
SIRS to standard of care treatment such as TACE are not yet avail-
able. Such trials will require a very large number of patients which
will not be easy to recruit in view of the already signiﬁcant use of
SIRS in clinical practice. The BCLC classiﬁcation provides clear
guidelines regarding the treatment options for the various stages
of HCC. Yet, so far, the role of SIRS still remains inconclusive.
Two recent surveys in Europe, although not comparable by
design, provide somewhat conﬂicting results regarding the use
of radioembolization in advanced HCC in Europe. In an Italian
survey conducted in 135 centers (with a questionnaire response
rate of 64.9%), only 2% of almost 9000 HCC patients were treated
by radioembolization [27]. However, another survey conducted
in 45 European centers (with a 62% questionnaire response rate)
reports the utilization of radioembolization in 1000 patients in
2009 and 1292 patients in 2010 [28]. This rising popularity of
SIRS is not translated into clinical guidelines as reﬂected in a quo-
tation from the recent EASL guidelines for management of HCC
[1]: ‘‘. . . Objective response rates (to SIRS) range from 35% to 50%.
Around 20% of patients present liver-related toxicity and 3% treat-
ment-related death. Despite the amount of data reported, there are
no RCT testing the efﬁcacy of 90Y radioembolization compared with
chemoembolization or sorafenib in patients at intermediate or
advanced stage, respectively. Further research trials are needed to
establish a competitive efﬁcacy role in these populations’’. Yet,
despite this reservation, the use of SIRS is expanding. Indeed, SIRS
is an attractive option for treatment of patients with advanced
and multifocal HCC. It is also at present the most promising treat-
ment modality for HCC patients with portal vein thrombosis; it644 Journal of Hepatology 201usually requires, in contrast to TACE, a single treatment session
(after proper pre-treatment evaluation) and it is effective in
downstaging of a large tumor mass. However, the few studies
on comparative efﬁcacy of SIRS vs. TACE are retrospective and
consequently it is not clear whether SIRS treatment provides a
survival advantage over TACE. Finally, SIRS treatment is expen-
sive and requires a specialized infrastructure for handling the
intra-arterial injection of 90Y.
In summary, the results of the present retrospective study
conﬁrm that SIRS is as safe and as effective in older patients
and in younger individuals with advanced HCC. Clinical experi-
ence suggests that SIRS treatment has the potential to provide
palliation to very sick older patients, probably even beyond the
age of 75 years with multifocal HCC with or without portal vein
thrombosis. However, before translating the already available
clinical experience into guideline, it is important to verify if SIRS
provides a survival advantage as compared to other standard of
care treatment modalities. The variable quality of data obtained
in previous retrospective clinical trials, the heterogeneous popu-
lation studied, and lack of standardization of tumor growth and
patient performance do not enable at present a clear cut endorse-
ment of this procedure. Yet, individual response rates to SIRS in
patients with advanced HCC are often quite impressive and this
treatment modality should remain available in the frame of con-
trolled prospective clinical trials in young and old patients alike.Conﬂict of interest
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